<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847376</url>
  </required_header>
  <id_info>
    <org_study_id>CR108331</org_study_id>
    <secondary_id>TMC278LAHTX2001</secondary_id>
    <nct_id>NCT03847376</nct_id>
  </id_info>
  <brief_title>Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection</brief_title>
  <official_title>Rilpivirine Long Acting Single Patient Requests</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <brief_summary>
    <textblock>
      The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long
      Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus
      (HIV)-1 infection as single patient request to individuals who have no available treatment
      alternatives and/or limited treatment options (for example, who are unable to participate in
      the Phase III clinical studies or do not qualify). RPV LA can only be provided if
      participants are also eligible for cabotegravir Long Acting injections.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>HIV</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilpivirine Long Acting (RPV LA)</intervention_name>
    <description>Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter [mL] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.</description>
    <other_name>JNJ-16150108-AAA</other_name>
  </intervention>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>1-800-JANSSEN (1-800-526-7736)</phone>
    <email>Janssenmedinfo@its.jnj.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rilpivirine</keyword>
  <keyword>Long Acting Rilpivirine Injection</keyword>
  <keyword>HIV</keyword>
  <keyword>Rilpivirine Expanded Access</keyword>
  <keyword>Rilpivirine Single Patient Request</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

